Company: UPC
Filing Date: 2025-02-03
Form Type: 6-K
Source: 0001213900-25-009434
Chunk: 0

Company: Universe Pharmaceuticals INC
Filing Date: 2025-02-03
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

Exhibits</div>

| Exhibit 
 No.     |     | Description                                                                              |
| 99.1    |     | Press Release –                                                                          
 Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request |

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Date: February 3, 2025 | Universe Pharmaceuticals INC. 
 By:                           | /s/                     
 Gang Lai                |
|:-----------------------|:------------------------------|:------------------------|
|                        |                               | Gang Lai                |
|                        |                               | Chief Executive Officer |

<div align='center'>2</div>